Work

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-6194

Authors: Olalekan Oluwole, Jennifer Benner, Madhu Palivela, Katalin Bognar, Nicholas Adair, Laura Cianciolo, Matthew Sussman, Markqayne Ray, Paola Ghione

Institutions: Vanderbilt University, Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7108710396

Cites:

Cited by:

Related to: